Stockscreener 앱 받기
7.37
3.08%
0.22
시간 외 거래:
7.42
0.05
+0.68%
전일 마감가:
$7.15
열려 있는:
$7.27
하루 거래량:
675.63K
Relative Volume:
0.64
시가총액:
$365.15M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.4011
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-1.86%
1개월 성능:
-12.99%
6개월 성능:
-44.50%
1년 성능:
-47.95%
1일 변동 폭
$7.1825
$7.435
1주일 범위
$6.56
$7.70
52주 변동 폭
$6.56
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.37 | 365.15M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Nippon Shinyaku, REGENXBIO partner for MPS treatments in U.S. and Asia -January 17, 2025 at 08:01 am EST - Marketscreener.com
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku - Scrip
REGENXBIO: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha
Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma
Regenxbio maintained at Buy rating by H.C. Wainwright post partnership announcement - Investing.com India
Regenxbio maintained at Buy by H.C. Wainwright post partnership announcement - Investing.com Australia
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright - MarketBeat
Regenxbio inks MPS drugs collab with Nippon Shinyaku - The Pharma Letter
AbbVie, REGENXBIO advance gene therapy for eye diseases By Investing.com - Investing.com Australia
Rockville’s RegenxBio Enters $810 Million Partnership with Japanese Firm to Launch New Treatments - The MoCoShow
Rockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon Shinyaku - Washington Business Journal
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive
Regenxbio stock hits 52-week low at $7.13 amid market challenges - Investing.com Australia
RegenXBio Partners with Nippon Shinyaku on Gene Therapies - TipRanks
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku By Investing.com - Investing.com Australia
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku - Investing.com
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - Longview News-Journal
Barclays PLC Raises Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases - Investing.com India
AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program - StreetInsider.com
AbbVie and REGENXBIO Advance Revolutionary One-Time Gene Therapy for Vision Loss Treatment - StockTitan
Regenxbio stock hits 52-week low at $7.13 amid market challenges By Investing.com - Investing.com South Africa
Regenxbio stock jumps 13% on positive data for DMD drug - MSN
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus.com
Jane Street Group LLC Sells 35,994 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio price target lowered to $22 from $25 at BofA - Yahoo Finance
JPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
JPMorgan Chase & Co. Cuts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Principal Financial Group Inc. Sells 11,064 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Geode Capital Management LLC Raises Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
RGNX stock touches 52-week low at $7.15 amid market challenges - Investing.com Australia
RGNX stock touches 52-week low at $7.15 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Purchases 67,948 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Barclays PLC Has $1.22 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December - MarketBeat
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive - Simply Wall St
(RGNX) Investment Analysis - Stock Traders Daily
Fmr LLC Boosts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):